Ratner Lab

Thomson, CS; Pundavela, J; Perrino, MR; Coover, RA; Choi, K; Chaney, KE; Rizvi, TA; Largaespada, DA; Ratner, N. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene. 2021; 40:4229-4241.

Galvin, R; Watson, AL; Largaespada, DA; Ratner, N; Osum, S; Moertel, CL. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23.

Vélez-Reyes, GL; Koes, N; Ryu, JH; Kaufmann, G; Berner, M; Weg, MT; Wolf, NK; Rathe, SK; Ratner, N; Moriarity, BS; et al. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13.

Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.

Oatman, N; Dasgupta, N; Arora, P; Choi, K; Gawali, MV; Gupta, N; Parameswaran, S; Salomone, J; Reisz, JA; Lawler, S; et al. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science advances. 2021; 7.

Na, Y; Hall, A; Choi, K; Hu, L; Rose, J; Coover, RA; Miller, A; Hennigan, RF; Dombi, E; Kim, MO; et al. MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene. 2021; 40:951-963.

Ma, Y; Gross, AM; Dombi, E; Pemov, A; Choi, K; Chaney, K; Rhodes, SD; Angus, SP; Sciaky, N; Clapp, DW; et al. A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 2020; 22:1786-1793.

Asleh, J; Shofty, B; Cohen, N; Kavushansky, A; Lopez-Juarez, A; Constantini, S; Ratner, N; Kahn, I. Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America. 2020; 117:22506-22513.

Palomo-Irigoyen, M; Pérez-Andrés, E; Iruarrizaga-Lejarreta, M; Barreira-Manrique, A; Tamayo-Caro, M; Vila-Vecilla, L; Moreno-Cugnon, L; Beitia, N; Medrano, D; Fernández-Ramos, D; et al. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. Journal of Clinical Investigation. 2020; 130:3848-3864.

Fletcher, JS; Pundavela, J; Ratner, N. After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances. 2020; 2:i23-i32.

Heinrich, A; Potter, SJ; Guo, L; Ratner, N; DeFalco, T. Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis. Cell Reports. 2020; 31.

Gripp, KW; Schill, L; Schoyer, L; Stronach, B; Bennett, AM; Blaser, S; Brown, A; Burdine, R; Burkitt-Wright, E; Castel, P; et al. The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics, Part A. 2020; 182:597-606.

Guo, J; Chaney, KE; Choi, K; Witek, G; Patel, AV; Xie, H; Lin, D; Whig, K; Xiong, Y; Schultz, DC; et al. Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. American Journal of Cancer Research. 2020; 10:856-869.

Na, Y; Huang, G; Wu, J. The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. Molecules and Cells. 2020; 43:153-159.

Yokota, A; Huo, L; Lan, F; Wu, J; Huang, G. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. Molecules and Cells. 2020; 43:145-152.

Yu, Y; Choi, K; Wu, J; Andreassen, PR; Dexheimer, PJ; Keddache, M; Brems, H; Spinner, RJ; Cancelas, JA; Martin, LJ; et al. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.

Isfort, I; Elges, S; Cyra, M; Berthold, R; Renner, M; Mechtersheimer, G; Aman, P; Larsson, O; Ratner, N; Hafner, S; et al. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. Scientific Reports. 2019; 9.

Choi, K; Ratner, N. iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform. BMC Genomics. 2019; 20.

Osum, S; Stemmer-Rachamimov, A; Widemann, B; Dombi, E; Vitte, J; Dahiya, S; Rizvi, T; Ratner, N; Messiaen, L; Gutmann, D; et al. TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1. Neuro-Oncology. 2019; 21:vi267-vi267.

Oatman, N; Dasgupta, N; Choi, K; Gawali, M; Gupta, N; Parameswaran, S; Lawler, S; Brennan, C; Wu, J; Sallans, L; et al. CBMT-05. GENETIC AND EPIGENETIC MECHANISMS REGULATING SCD INHIBITOR SENSITIVITY IN GLIOBLASTOMA. Neuro-Oncology. 2019; 21:vi33-vi33.

Ramkissoon, A; Chaney, KE; Milewski, D; Williams, KB; Williams, RL; Choi, K; Miller, A; Kalin, TV; Pressey, JG; Szabo, S; et al. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Clinical Cancer Research. 2019; 25:4117-4127.

Rauen, KA; Alsaegh, A; Ben-Shachar, S; Berman, Y; Blakeley, J; Cordeiro, I; Elgersma, Y; Evans, DG; Fisher, MJ; Frayling, IM; et al. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. American Journal of Medical Genetics, Part A. 2019; 179:1091-1097.

Rice, FL; Houk, G; Wymer, JP; Gosline, SJ C; Guinney, J; Wu, J; Ratner, N; Jankowski, MP; La Rosa, S; Dockum, M; et al. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin. PLoS ONE. 2019; 14.

Hall, A; Choi, K; Liu, W; Rose, J; Zhao, C; Yu, Y; Na, Y; Cai, Y; Coover, RA; Lin, Y; et al. RUNX represses Pmp22 to drive neurofibromagenesis. Science advances. 2019; 5.

Hennigan, RF; Fletcher, JS; Guard, S; Ratner, N. Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. Science Signaling. 2019; 12.

Fletcher, JS; Springer, MG; Choi, K; Jousma, E; Rizvi, TA; Dombi, E; Kim, M; Wu, J; Ratner, N. STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene. 2019; 38:2876-2884.

Fletcher, JS; Wu, J; Jessen, WJ; Pundavela, J; Miller, JA; Dombi, E; Kim, M; Rizvi, TA; Chetal, K; Salomonis, N; et al. Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI insight. 2019; 4.

Agresta, L; Salloum, R; Hummel, TR; Ratner, N; Mangano, FT; Fuller, C; McMasters, RL; Pater, L; Jones, BV; Szabo, S; et al. Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. Pediatric Blood and Cancer. 2019; 66.

Rauen, KA; Schoyer, L; Schill, L; Stronach, B; Albeck, J; Andresen, BS; Cave, H; Ellis, M; Fruchtman, SM; Gelb, BD; et al. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. American Journal of Medical Genetics, Part A. 2018; 176:2924-2929.

Isakson, SH; Rizzardi, AE; Coutts, AW; Carlson, DF; Kirstein, MN; Fisher, J; Vitte, J; Williams, KB; Pluhar, GE; Dahiya, S; et al. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology. 2018; 1.

Modur, V; Singh, N; Mohanty, V; Chung, E; Muhammad, B; Choi, K; Chen, X; Chetal, K; Ratner, N; Salomonis, N; et al. Defective transcription elongation in a subset of cancers confers immunotherapy resistance. Nature Communications. 2018; 9.

Coover, RA; Healy, TE; Guo, L; Chaney, KE; Hennigan, RF; Thomson, CS; Aschbacher-Smith, LE; Jankowski, MP; Ratner, N. Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1. Acta neuropathologica communications. 2018; 6.

Chhipa, RR; Fan, Q; Anderson, J; Muraleedharan, R; Huang, Y; Ciraolo, G; Chen, X; Waclaw, R; Chow, LM; Khuchua, Z; et al. AMP kinase promotes glioblastoma bioenergetics and tumour growth. Nature Cell Biology. 2018; 20:823-835.

Weiss, B; Plotkin, S; Widemann, B; Tonsgard, J; Blakeley, J; Allen, J; Schorry, E; Korf, B; Rosser, T; Goldman, S; et al. NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Neuro-Oncology. 2018; 20:i143-i143.

Fisher, MJ; Belzberg, AJ; de Blank, P; De Raedt, T; Elefteriou, F; Ferner, RE; Giovannini, M; Harris, GJ; Kalamarides, M; Karajannis, MA; et al. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. American Journal of Medical Genetics, Part A. 2018; 176:1258-1269.

Allaway, RJ; Wood, MD; Downey, SL; Bouley, SJ; Traphagen, NA; Wells, JD; Batra, J; Melancon, SN; Ringelberg, C; Seibel, W; et al. Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Oncotarget. 2018; 9:15860-15875.

Wu, LM N; Deng, Y; Wang, J; Zhao, C; Wang, J; Rao, R; Xu, L; Zhou, W; Choi, K; Rizvi, TA; et al. Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. Cancer Cell. 2018; 33:292-308.e7.

Titus, HE; Lopez-Juarez, A; Silbak, SH; Rizvi, TA; Bogard, M; Ratner, N. Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling. GLIA. 2017; 65:1990-2002.

Maertens, O; McCurrach, ME; Braun, BS; De Raedt, T; Epstein, I; Huang, TQ; Lauchle, JO; Lee, H; Wu, J; Cripe, TP; et al. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research. 2017; 77:5706-5711.

Haworth, KB; Arnold, MA; Pierson, CR; Choi, K; Yeager, ND; Ratner, N; Roberts, RD; Finlay, JL; Cripe, TP. Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: Implications for immunotherapy. Oncotarget. 2017.

Reilly, KM; Kim, A; Blakely, J; Ferner, RE; Gutmann, DH; Legius, E; Miettinen, MM; Randall, RL; Ratner, N; Jumbe, NL; et al. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. Journal of the National Cancer Institute. 2017; 109.

Anderson, JL; Muraleedharan, R; Oatman, N; Klotter, A; Sengupta, S; Waclaw, RR; Wu, J; Drissi, R; Miles, L; Raabe, EH; et al. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Neuro-Oncology. 2017; 19:1068-1078.

Lopez-Juarez, A; Titus, HE; Silbak, SH; Pressler, JW; Rizvi, TA; Bogard, M; Bennett, MR; Ciraolo, G; Williams, MT; Vorhees, CV; et al. Oligodendrocyte Nf1 Controls Aberrant Notch Activation and Regulates Myelin Structure and Behavior. Cell Reports. 2017; 19:545-557.

Choi, K; Komurov, K; Fletcher, JS; Jousma, E; Cancelas, JA; Wu, J; Ratner, N. An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Scientific Reports. 2017; 7.

Wu, J; Liu, W; Williams, JP; Ratner, N. EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation. Oncogene. 2017; 36:1669-1677.

Currier, MA; Sprague, L; Rizvi, TA; Nartker, B; Chen, C; Wang, P; Hutzen, BJ; Franczek, MR; Patel, AV; Chaney, KE; et al. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. Oncotarget. 2017; 8:17412-17427.